A novel BAFF-CAR-T, which targets 3 sites unique to cancer cells, including a target called BAFF, which is under development in collaboration with Luminary Therapeutics to treat multiple myeloma and lymphoma patients [40]. This evidence concerns the gene TNFSF13B and plasma cell myeloma.